At Impact, we are experts in maximizing biosimilar uptake, adoption and market-share growth and maintenance through partnerships with global biosimilars, such as infliximab and adalimumab.

Our experience supporting a wide range of medical and commercial teams to achieve their critical success factors has provided us with a unique depth of expertise to help companies achieve success whatever the market scenario

Market scenario

Little or no biosimilar experience

Biosimilars are new or recent in your market or therapeutic area.

Critical success factor:

Rapidly establish biosimilar confidence to drive uptake.

Challenges:

  • Concerns about the approval process and limited study data
  • Reluctance to move stable patients from the originator

 

Biosimilar experience, but not for your molecule

One  of the first biosimilars to a molecule entering an experienced market and/or therapeutic area. 

Critical success factor:

Build advocacy for rapid uptake and market share maintenance.

Challenges:

  • Creating brand advocates through clinically compelling programmes
  • Past experiences of switching to a biosimilar may not have been positive for the MDT

Crowded market

There are many biosimilars  already on the market (or launching at a similar time to you), and/or many competitors of the same molecule.

Critical success factor:

Clearly defined position and offering to secure market share.

Challenges:

  • Securing market share already stretched across multiple competitors
  • Differentiating a brand beyond the molecule and cost

Asking the right questions is the first step to overcoming these challenges.

What should you ask yourself?

Little or no biosimilar experience

  • Who are your advocates?
  • How convinced are HCPs about the benefits of biosimilars?
  • How confident are they in the biosimilar regulatory process?

  • What are the proportions of new starters and switch patients?

Biosimilar experience, but not for your molecule

  • How well do you understand the market dynamics affecting biosimilar adoption?
  • How extensively are you supporting patients through a switch?
  • How can existing biosimilar experience be leveraged?

Crowded market

 

  • How can you differentiate your product beyond price?

  • How can you support patients / HCPs?

  • Which product attributes should you highlight to providers, patients and payers?

  • What added value activities will support brand differentiation?

We have supported biosimilar brands in each of these scenarios, so we know what success looks like and how you can achieve it.

What can we do to help you achieve your critical success factors?

Little or no biosimilar experience

Impact case examples:

  • Bitesize digital materials to educate HCPs and patients on biosimilar benefits and fundamentals
  • HCP webinars with KOL insights into why and how to switch to a biosimilar
  • Service-oriented resources to facilitate successful biosimilar switches
  • Patient organization roundtable to share learnings from experienced therapy areas

Biosimilar experience, but not for your molecule

Impact case examples:

  • ‘Exchange’ initiative to facilitate peer-to-peer learning and increase HCP confidence in biosimilars
  • Training materials to optimize switching discussions and minimize nocebo effect
  • Self-led learning programs tailored to each HCP’s knowledge of biosimilars
  • Innovative augmented reality video explaining complex data in a simple way

Crowded market

Impact case examples:

  • Analysis of competitor offerings and potential gaps or opportunities
  • Optimized brand positioning and core messaging to differentiate beyond molecule and cost
  • Value-added educational support materials
  • Comprehensive and digestible internal training decks on the competitor landscape

Whatever your market scenario, our team is here to support you with addressing the unique challenges facing your biosimilar brand.

Not launching a biosimilar right now?

Established biosimilar defending its position

Market scenarios: defending your established biosimilar

Marketing a portfolio of therapies

Market scenarios: the portfolio approach

Or return to the biosimilars home page

Impact: biosimilar specialists

Accelerating the uptake of your biosimilar